礼来将以12亿美元收购Ventyx

Core Viewpoint - Eli Lilly (LLY) has agreed to acquire Ventyx Biosciences (VTYX) in an all-cash transaction to expand its oral small molecule therapy product line targeting chronic inflammatory diseases [1]. Group 1 - Eli Lilly's stock decreased by 0.2% in early trading on Thursday [1]. - The acquisition aims to enhance Eli Lilly's portfolio in the area of chronic inflammation [1].